All these elements underline the importance of targeting IL-6-mediated inflammatory pathways in SLE, especially in patients with elevated IL-6 and CRP levels and uncontrolled disease despite first-line therapies. The gene discussed is CRP; the disease is systemic lupus erythematosus.